MET and prostate carcinoma: HGF is abundantly expressed in the microenvironment of metastatic prostate cancer in the bone, and high HGF levels are often associated with metastatic PCa to bone, suggesting that HGF is a key component of regulating HGF/MET signaling in mCRPC [30].